Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedNon-substantive metadata updates were made: a general note about voluntary publication submissions was added (2025-11-25), the 'Last Update Posted (Estimated)' field was updated (2025-11-20), and an earlier PubMed-based publication note and prior 'Last Update Posted' entry were removed (September 2024).SummaryDifference0.2%

- Check15 days agoChange DetectedThe Publications section was updated to clarify that PubMed items are auto-filled and to specify the page revision numbers (v3.3.2 vs v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check22 days agoChange DetectedLocation entry changed from Tainan City, Taiwan, 70403 to Tainan, Taiwan, 70403; the government funding lapse notice banner was removed.SummaryDifference0.3%

- Check37 days agoChange DetectedThe differences are minor UI and formatting adjustments to the Study Details page without changes to core study data such as eligibility criteria, primary outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check51 days agoChange DetectedMinor metadata update: the citation’s online-ahead-of-print note and date formatting were adjusted; core study information remains the same.SummaryDifference0.6%

- Check65 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.